Current Ongoing Studies
Download PDF flyer of this study
The Alzheimer's Disease Neuroimaging Initiative - 2 (ADNI2) study is a newly funded NIA study that builds upon the previous ADNI1 and ADNI-GO studies. This study will continue to follow ADNI-GO and ADNI1 subjects longitudinally for an additional 5 years. In addition, ADNI2 will recruit new subjects from one of four groups of individuals: cognitively normal (CN), eMCI (early mild cognitive impairment), IMCI (late mild cognitive impairment), and mild-AD. This study aims to follow all subjects except for the mild-AD subjects (mild AD subject participation will end at 24 months) for up to 54 months by employing body fluid (blood, urine, CSF), neuropsychological testing, braing MRIs and PET scans at different time points throughout the subject's participation. ADNI2 is a non randomized longitudinal study that offers no drug or investigational treatment.
Other Clinical Trial Resources
ADEAR Clinical Trials Database - The Alzheimer's Disease Education & Referral Center (ADEAR) clinical trials database provides detailed information - background, eligibility criteria, site listings, and references - on Alzheimer's disease research studies sponsored by the National Institute on Aging, other NIH institutes, private organizations, and industry.
This page last updated Nov 20, 2012